These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 3547921)

  • 1. Type II hyperlipoproteinemia, hyperapobetalipoproteinemia, and hyperalphalipoproteinemia following renal transplantation: prevalence and precipitating factors.
    Lowry RP; Soltys G; Mangel R; Kwiterovitch P; Sniderman AD
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2229-32. PubMed ID: 3547921
    [No Abstract]   [Full Text] [Related]  

  • 2. Type II hyperlipoproteinemia, hyperapobetalipoproteinemia, and hyperalphalipoproteinemia following renal transplantation: implications for atherogenic risk.
    Lowry RP; Soltys G; Peters L; Mangel R; Sniderman AD
    Transplant Proc; 1987 Aug; 19(4):3426-30. PubMed ID: 3303510
    [No Abstract]   [Full Text] [Related]  

  • 3. [Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia].
    Saitta A; Bonaiuto M; Lanzafame F; Mileto A; Pernice F; Cinquegrani M; Mazza G; Micali G; Pangallo A; Fodale P
    Clin Ter; 1988 Mar; 124(5):373-81. PubMed ID: 2974348
    [No Abstract]   [Full Text] [Related]  

  • 4. Dyslipoproteinemias after heart and heart-lung transplantation: potential relation to accelerated graft arteriosclerosis.
    Bilodeau M; Fitchett DH; Guerraty A; Sniderman AD
    J Heart Transplant; 1989; 8(6):454-9. PubMed ID: 2614546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hyperlipoproteinemia, HDL-cholesterol and arteriosclerosis indices].
    Herrmann W; Reuter W
    Z Gesamte Inn Med; 1982 Dec; 37(24):830-3. PubMed ID: 6963524
    [No Abstract]   [Full Text] [Related]  

  • 6. [Plasma exchange therapy in a patient with familial hypercholesteremia and generalized arteriosclerosis].
    Schrecker O; Thies K; Schlierf G
    Internist (Berl); 1984 Sep; 25(9):574-6. PubMed ID: 6386739
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effects of bezafibrate on lipoprotein lipids and apolipoproteins B and A1 in patients with primary hypercholesterolemia].
    Branchi A; Sommariva D; Tirrito M; Bonfiglioli D; Pini C; Scandiani L; Orlandi S; Fasoli A
    Clin Ter; 1987 Jul; 122(1):17-23. PubMed ID: 2973892
    [No Abstract]   [Full Text] [Related]  

  • 8. Triglyceride and Lp(a) concentrations in hyperapobetalipoproteinemia.
    Sorell L; Simón R
    Clin Chim Acta; 2000 Apr; 294(1-2):199-203. PubMed ID: 10809583
    [No Abstract]   [Full Text] [Related]  

  • 9. [Arteriosclerosis. II. Pathogenesis of dyslipoproteinemia].
    Cybulska B; Kłosiewicz-Latoszek L
    Wiad Lek; 1985 Aug; 38(15):1097-103. PubMed ID: 4072207
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of type IIa and type V hyperlipoproteinemia and of a normal volunteer by continuous LDL-apheresis.
    Riesen WF; Sturzenegger E; Imhof C; Descoeudres C; Mordasini R; Oetliker OH
    Prog Clin Biol Res; 1988; 255():337-46. PubMed ID: 3422496
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute lipidemic effect of calcium heparin in normolipemic and hyperlipemic subjects.
    Ferlito S; Ricceri M; Ossino AM
    Int Angiol; 1989; 8(3):140-4. PubMed ID: 2592796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [HDL, HDL2 and HDL3 cholesterol in various types of hyperlipoproteinemia in relation to clinical signs of arteriosclerosis].
    Sznajderman M; Zawadzki Z
    Kardiol Pol; 1986; 29(3):194-203. PubMed ID: 3773408
    [No Abstract]   [Full Text] [Related]  

  • 13. Hyperapobetalipoproteinaemia: an emerging risk factor for atherosclerosis.
    Thompson GR; Trayner IA; Allaway SL; Robinson D; Ritchie CD
    Monogr Atheroscler; 1986; 14():129-31. PubMed ID: 3736551
    [No Abstract]   [Full Text] [Related]  

  • 14. Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia, and familial hypercholesterolemia.
    Teng B; Thompson GR; Sniderman AD; Forte TM; Krauss RM; Kwiterovich PO
    Proc Natl Acad Sci U S A; 1983 Nov; 80(21):6662-6. PubMed ID: 6579550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications?
    Badiou S; Garrigue V; Dupuy AM; Chong G; Cristol JP; Mourad G
    Transplant Proc; 2006 Sep; 38(7):2314-6. PubMed ID: 16980076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical research on the hypolipidemic action of a probucol preparation].
    Naumova R; Kerekovska M; Goranov I; Balabanski L
    Vutr Boles; 1986; 25(2):73-7. PubMed ID: 3716382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hyperlipoproteinemia in the production of atherosclerosis. Risk factors: diagnosis and treatment].
    Pedraza A
    Rev Fac Cien Med Univ Nac Cordoba; 1993; 51(1):21-33. PubMed ID: 7809452
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of dietary treatment on the plasma levels of lipids, lipoprotein cholesterol and LDL B protein in children with type II hyperlipoproteinemia.
    Kwiterovich PO; Bachorik PS; Franklin FA; Margolis S; Georgopoulos L; Teng B; Sniderman AD
    Prog Clin Biol Res; 1985; 188():123-37. PubMed ID: 4059254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Monitoring of lipid anomalies in renal transplantation].
    Mourad G; Vela C; Cristol JP
    Nephrologie; 2000; 21(7):365-6. PubMed ID: 11200613
    [No Abstract]   [Full Text] [Related]  

  • 20. [Arteriosclerosis. III. Laboratory diagnosis of dyslipoproteinemia].
    Nowicka G; Kłosiewicz-Latoszek L
    Wiad Lek; 1985 Aug; 38(16):1179-84. PubMed ID: 4082589
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.